Zhaoke Ophthalmology-B (06622) announced that it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore. The company has also established a strategic partnership with the leading Asian ophthalmic company Senju Pharmaceutical Co., Ltd. (Senju) to commercialize the product in Vietnam. Zhaoke has granted AFT and Senju exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets. Through these agreements, AFT and Senju become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion. BRIMOCHOL™ PF is a potential therapy for correcting the loss of near vision due to presbyopia and is a core asset licensed by the company through its partner Tenpoint Therapeutics, Ltd. (Tenpoint). Tenpoint is a global, commercially-ready biotechnology company developing breakthrough therapies to restore vision in aging eyes. In June 2025, Tenpoint announced that the U.S. FDA had accepted the New Drug Application for this product. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for BRIMOCHOL™ PF, with a review deadline of January 28, 2026.